Cognate BioServices, a Charles River Company

Cognate BioServices, founded in 2002, is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. The company's slogan, "Your CDMO Partner from Concept to Commercial for Cell & Gene Therapy Products," encapsulates its mission. With a focus on providing a broad range of commercialization services to regenerative medicine, cellular immunotherapy, and advanced cell therapy companies, Cognate offers a unique combination of custom services across all points of clinical and commercial development. This includes early preclinical studies, mid-phase trials, product scale-up, later-stage clinical trials, and bridging into commercial manufacturing. Based in the United States, Cognate BioServices has garnered attention with its most recent Series B investment on 21 January 2020. Noteworthy investors in this round included EW Healthcare Partners and Medivate Partners. As an organization that prides itself on its quality and experience, Cognate applies the know-how and expertise of its business, scientific, and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms, from start to finish. With a strong focus on biotechnology, health care, and manufacturing industries, Cognate BioServices continues to play a pivotal role in advancing cell and gene therapies for the betterment of medical science.